Abstract
<div>Abstract<p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most life-threatening malignancies. Although the deoxycytidine analog gemcitabine has been used as the first-line treatment for PDAC, the primary clinical challenge arises because of an eventual acquisition of resistance. Therefore, it is crucial to elucidate the mechanisms underlying gemcitabine resistance to improve treatment efficacy. To investigate potential genes whose inactivation confers gemcitabine resistance, we performed CRISPR knockout (KO) library screening. We found that deoxycytidine kinase (<i>DCK</i>) deficiency is the primary mechanism of gemcitabine resistance, and the inactivation of <i>CRYBA2</i>, <i>DMBX1</i>, <i>CROT</i>, and <i>CD36</i> slightly conferred gemcitabine resistance. In particular, gene expression analysis revealed that <i>DCK</i> KO cells displayed a significant enrichment of genes associated with MYC targets, folate/one-carbon metabolism and glutamine metabolism pathways. Evidently, chemically targeting each of these pathways significantly reduced the survival of <i>DCK</i> KO cells. Moreover, the pathways enriched in <i>DCK</i> KO cells represented a trend similar to those in PDAC cell lines and samples of patients with PDAC with low <i>DCK</i> expression. We further observed that short-term treatment of parental CFPAC-1 cells with gemcitabine induces the expression of several genes, which promote synthesis and transport of glutamine in a dose-dependent manner, which suggests glutamine availability as a potential mechanism of escaping drug toxicity in an initial response for survival. Thus, our findings provide insights into novel therapeutic approaches for gemcitabine-resistant PDAC and emphasize the involvement of glutamine metabolism in drug-tolerant persister cells.</p>Implications:<p>Our study revealed the key pathways involved in gemcitabine resistance in PDAC, thus providing potential therapeutic strategies.</p></div>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
